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Abstract 
 
To assess the efficacy of single dose of octreotide and compare it with another antisecretory agent racecadotril in the 
management of acute infective diarrhoea. A Randomised control study was carried out on the acute diarrhoeal 
disease patients who were admitted to the Department of General Medicne at R.L. Jalappa Hospital and Research 
Center, Tamaka, Kolar. 90 patients (≥ 18 years of age) with moderate to severe acute diarrheal illness of less than 5 
days duration were randomly allotted into 3 treatment categories of 30 patients each with the help of random number 
table method after taking written informed consent from them. The control group received only fluids and 
antibiotics, the racecadotril group received fluid, antibiotics and oral racecadotril at dose of 1.5 mg/kg three times a 
day. The octreotide group received octreotide (100 microgram stat at the time of hospitalization) along with fluid 
and antibiotics. Fluid was given according to the severity of dehydration. Intravenous ciprofloxacin and 
metronidazole were given to all the patients. A detailed history and clinical examination was done in all patients. 
Routine blood investigations and stool examination was carried out. All the patients in the three groups were 
matched for age and sex. 81.1% of patients (73/90) were males and majority of them belonged to 25-44 age group. 
74.4% of them (67/90) belonged to Lower Class as per Modified B G Prasads Classification. 47 out 90 were from 
Rural Area. This study results have shown that provide that Octreotide is an effective treatment for acute infective 
diarrhoea in adults who were admitted and were of unknown etiology. As compared with the control and 
Racecadotril groups, the Octreotide group had clinically consistent and significant results with respect to the 
Duration of diarrhoea, Stool Volume and Fluid requirement for the management. 
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Introduction 
 
Infections with bacteria, viruses, and parasites are the 
most important cause of acute diarrhea; while bacteria 
are the leading cause of acute diarrhea in the 
developing countries, viruses are its most frequent 
cause in industrialized countries.[1] Transmission 
occurs in most cases via contaminated water or 
foodborne.[2] Acute infectious diarrhea continues to 
cause high morbidity and mortality worldwide. 
Although oral rehydration therapy has reduced the 
mortality associated with acute diarrhea, the diarrheal 
attack remains unchanged and stool volume often 
increases during rehydration process.[3]  
___________________________ 
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As dehydration is the most frequent cause of death in 
acute diarrhea, oral rehydration therapy is the most 
important component of treatment. Its increasing use 
has been associated with a major reduction in deaths 
due to acute diarrhea.[1] While infectious acute 
diarrhea tends to be self-limiting in otherwise healthy 
people, it is not only unpleasant but also has social 
impact such as lost working days.[4] Moreover, even in 
adults in industrialized countries, diarrhea may lead to 
death due to visceral failure secondary to dehydration, 
particularly in the elderly.[5]In recent years, the 
standard of therapy of acute diarrhea involves 
antibiotics, fluid and anti-diarrheal agents. There are a 
variety of anti-diarrheal agents already available in the 
market– e.g. racecadotril, loperamide, diphenoxylate 
etc. However all these agents have many drawbacks. 
A number of potential targets for antisecretory agents 
have emerged which include loci within the enterocyte 
(chloride channel, calcium calmodulin) and recently 
enteric nerves and endogenous mediators (5-HT, 
substance P, VIP).[6] 
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Racecadotril, an enkephalinase inhibitor, potentiates 
the action of enkephalins which are endogenous 
opiods, antisecretory activity occurs mainly through 
delta receptor activation.2However its antisecretory 
activity is weak.[6-9] 
Octreotide is a somatostatin analogue which has 
documented antisecretory activity in neuroendocrine 
tumors of GIT like VIPoma, gastrinoma and carcinoid 
syndrome.[10,11] There are reports that somatostatin 
and its analogues can inhibit intestinal secretions in 
VIPoma patients in absence of reduction of plasma VIP 
indicating that antisecretory activity may be operating 
through a direct effect either on enterocyte nervous 
system or enterocyte itself.[11] 
In view of the antisecretory role of octreotide in 
neuroendocrine tumors and cholera,[12] and much data   
available about the role of octreotide in acute 
gastroenteritis. So, this was planned to establish the 
role and to fill up the lacunae regarding octreotide in 
acute gastroenteritis. 
 
Objectives 
 
To assess the efficacy of single dose of octreotide and 
compare it with another antisecretory agent 
racecadotril in the management of acute infective 
diarrhoea. 
 
Materials and Methods 
 
A Randomised control study was carried out on the 
acute diarrhoeal disease patients who were admitted to 
the Department of General Medicne at R.L. Jalappa 
Hospital and Research Center, Tamaka, Kolar. 90 
patients (≥ 18 years of age) with moderate to severe 
acute diarrheal illness of less than 5 days duration were 
randomly allotted into 3 treatment categories of 30 
patients each with the help of random number table 
method after taking written informed consent from 
them. 
The control group received only fluids and antibiotics, 
the racecadotril group received fluid, antibiotics and 
oral racecadotril at dose of 1.5 mg/kg three times a day. 
The octreotide group received octreotide (100 
microgram stat at the time of hospitalization) along 
with fluid and antibiotics. Fluid was given according to 
the severity of dehydration. Intravenous ciprofloxacin 
and metronidazole were given to all the patients. A 
detailed history and clinical examination was done in 
all patients. Routine blood investigations and stool 
examination was carried out. 
Study Variables 
 
1. Frequency of stools- Number of stools passed by the 
patients in 24 hours was counted by attendant and duty 
doctor. 
2. Quantity of stool per day- Patients’ attendants were 
asked to bring calibrated jar and instructed to collect 
stool in jar. Quantity of each stool was noted by the 
duty doctor. 
3. Fluid requirement per day- fluid requirement in litres 
was calculated by adding total amount of IV fluid plus 
oral intake of liquids. 
 
Statistical analysis – Data were entered in excel sheet 
and analyzed with help of IBM SPSS 22 Version. 
Quantitative data were summarized in form of mean ± 
S.D and average value of different treatment groups 
were compared using ANOVA test (analysis of 
variance) and post hoc test. Qualitative data were 
summarized in form of proportions and analyzed using 
chi square test. For all statistical analysis, level of 
confidence was kept 95%. 
 
Institutional Ethical Clearance was taken before the 
study was started. All the information was kept 
confidential and was used only for research Purpose. 
Written informed consent was taken from all the 
participants who took part in the study.  
 
Results 
 
All the patients in the three groups were matched for 
age and sex. 81.1% of patients (73/90) were males and 
majority of them belonged to 25-44 age group. 74.4% 
of them (67/90) belonged to Lower Class as per 
Modified B G Prasads Classification. 47 out 90 were 
from Rural Area. 
 
Table 1 shows mean (±SE) frequency of stools in all 
groups at the time of admission. On day 2 the average 
frequency of stools passed in the octreotide group was 
2.05±1.71.It was almost the same in the control and 
racecadotril group at 6.54±2.41 and6.21±2.57 
respectively (p<0.001). Diarrhea stoppedin 53.3% of 
patients (16/30) in octreotide group by day 3 and allthe 
patients by day 4. Nearly 43.3% of patients (13/30) in 
controlgroup and 50% (15/30) in racecadotril group 
continued to have diarrhea by day 4. 
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Table 1: Day-wise average frequency of stools in different treatment groups 
 
Day Control 
Group 
Racecadotril 
Group 
 
Octreotide 
Group 
ANOVA 
 
Post hoc test (Tukeys test) 
p value 
 
Control  
vs 
Racecadotril 
 
Control 
 vs 
Octreotide 
 
Racecadotril 
vs 
Octreotide 
 
Admission 11.47±2.91 
(n=30) 
 
12.67±3.12 
(n=30) 
 
13.83±7.21 
(n=30) 
 
>0.05 >0.05 >0.05 >0.05 
2ND 6.54±2.41 
(n=28) 
 
6.21±2.57 
(n=30) 
 
2.05±1.71 
(n=30) 
 
<0.001 >0.05 <0.001 <0.001 
3RD 3.59±1.41 
(n=26) 
 
3.13±1.69 
(n=24) 
 
1.63±0.67 
(n=14) 
 
    
4TH 1.97±1.09 
(n=13) 
 
2.05±1.31 
(n=15) 
 
_ 
 
    
5TH 1.71±0.39 
(n=6) 
 
1.78±0.29 
(n=3) 
 
_ 
 
    
 
The mean (±SE) quantity of stools passed (in ml) was same at the time of admission in all three groups (Table 2). 
On day 2 it was 382.1±178.17 ml in octreotide group, as compared to 717.0±292.84 ml in control group and 
597.47±267.14 in racecadotril group. Thus there was a 57% and 39% reduction in stool quantity in octreotide group 
compared from control and racecadotril group respectively. 
 
Table 2: Day-wise average quantity of stools passed (in ml) in different treatment groups 
Day Control 
Group 
Racecadotril 
Group 
 
Octreotide 
Group 
ANOV
A 
 
Post hoc test (Tukeys test) 
p value 
 
Control  
vs 
Racecadotri
l 
 
Control 
 vs 
Octreotid
e 
 
Racecadotri
l vs 
Octreotide 
 
Admissio
n 
1208±421.0
0 
(n=30) 
1128.00±389.0
5 
(n=30) 
1270±967.31 
(n=30) 
>0.05 >0.05 >0.05 >0.05 
2ND 717.0±292.8
4 
(n=28) 
597.47±267.14 
(n=30) 
382.1±178.1
7 
(n=30) 
<0.001 >0.05 <0.001 <0.001 
3RD 381.64±174.
8 
(n=26) 
324.37±171.38 
(n=24) 
178.67±55.6
4 
(n=14) 
    
4TH 247.4±88.49 
(n=13) 
212.2±102.14 
(n=15) 
_ 
 
    
5TH 189.52±26.2
9 
(n=6) 
133.00±29.26 
(n=3) 
_ 
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On day 1 the average fluid (in litres) required in octreotide group was 5.03±1.71 
litres, as compared to 5.23±0.81 litres in control and 5.14±0.50  in racecadotril group respectively (Table 3). The 
respective values on day 2 were 3.47±0.39 litres for octreotide group; while it was 4.23±0.49litres for control group 
and 4.11±0.63 litres for racecadotril group respectively. Thusmean (±SE) quantity of fluid required was least in 
octreotide group (p<0.001). 
 
Table 3 : Mean±SD average quantity of fluid required (intravenous and oral, in litres) in all 3 groups 
Day Control 
Group 
Racecadotril 
Group 
 
Octreotide 
Group 
ANOVA 
 
Post hoc test (Tukeys test) 
p value 
 
Control  
vs 
Racecadotril 
 
Control 
 vs 
Octreotide 
 
Racecadotril 
vs 
Octreotide 
 
Admission 5.23±0.81 
(n=30) 
5.14±0.50 
(n=30) 
5.03±1.71 
(n=30) 
>0.05 >0.05 >0.05 >0.05 
2ND 4.23±0.49 
(n=28) 
4.11±0.63 
(n=30) 
3.47±0.39 
(n=30) 
<0.001 >0.05 <0.001 <0.001 
3RD 3.32±0.74 
(n=26) 
3.55±0.55 
(n=24) 
3.18±0.21 
(n=14) 
    
4TH 3.16±0.63 
(n=13) 
3.14±0.41 
(n=15) 
_ 
 
    
5TH 3.03±0.09 
(n=6) 
3.07±1.64 
(n=3) 
_ 
 
    
 
Discussion 
 
Diarrhea occurs as a result of increased intestinal 
secretion or decreased intestinal absorption or a 
combination of both. It is now well established that 
enteric nervous system is involved in the promotion of 
intestinal secretory process. A potent inhibitor of 
enkephalinase, racecadotril offers a novel and 
promising approach to the control of secretory 
diarrhea.[7] 
 
Eduardo et al. showed that treatment with racecadotril 
and oral rehydration therapy was more effective than 
oral rehydration alone in the treatment of acute watery 
diarrhea in children  which were consistent with the 
present study findings.[9] 
 
Loperamide and diphenoxylate are orally active 
antidiarrheal agent act by intestinal μ opiate receptors, 
leading to increased intestinal transit time. Side effects 
include constipation and bacterial overgrowth and 
hence can be harmful hence their use is controversial. 
 
Octreotide has also been evaluated in a randomized 
studyin patients with cholera by Moid I Khan et al. 
Patients were treated conventionally with fluid and 
antibiotics, but in addition were randomized to receive 
octreotide or placebo. There was a reduction in stool 
volume, frequency and duration of diarrhea with 
octreotide.[12] Similar results were observed by this 
study as well.  
 
The results of the present study show that octreotide is 
effective in treatment of acute watery diarrhea. As 
compared to the control and racecadotril group, the 
octreotide group had clinically consistent and 
significant (p<0.001) reduction in the frequency and 
volume of stools passed. The fluid requirement was 
also least in the octreotide group. Similar findings were 
observed in a RCT done by Mehta S et al at a tertiary 
care hospital.[13] 
 
Conclusion 
 
This study results have shown that provide that 
Octreotide is an effective treatment for acute infective 
diarrhoea in adults who were admitted and were of 
unknown etiology. As compared with the control and 
Racecadotril groups, the Octreotide group had 
clinically consistent and significant results with respect 
to the Duration of diarrhoea, Stool Volume and Fluid 
requirement for the management. 
 
Hence, octreotide as an antisecretory agent is very 
effective in management of acute infective diarrhoea in 
adults. Moreover, that study unfortunately has not 
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reported on adverse events observed with the two 
treatments. Additional studies will be required to 
define the benefit/ risk ratios of octreotide and 
racecadotril in patients with severe diarrhoea requiring 
hospitalization. 
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